Berkshire Biomedical Corporation has launched an equity crowdfunding campaign on StartEngine to support the development of its proprietary Computerized Oral Prescription Administration (COPA™) system, a novel technology designed to revolutionize medication delivery for patients with opioid use disorder (OUD) and other chronic conditions.
The Dallas-based medical device company announced the public investment opportunity on February 24, 2025, allowing individual investors to participate in advancing a technology that addresses critical challenges in medication adherence and security.
"We are incredibly excited to open this equity crowdfunding opportunity for individual investors to become a part of Berkshire's journey," stated John Timberlake, Chief Executive Officer of Berkshire. "Our goal is to enhance patient wellness by leveraging technology to improve medical outcomes."
How COPA™ Technology Works
The COPA™ system is a handheld, automated oral liquid dispensing device that delivers precise doses of controlled and non-controlled prescription medications. What distinguishes the technology is its dual biometric authentication system, which verifies user identity through both fingerprint and dentition scans before dispensing medication.
This proprietary authentication approach ensures that only the Authenticated Intended User (AIU™) can access their prescribed medication, addressing concerns about medication diversion and misuse that are particularly relevant for controlled substances.
The system also features cloud-based connectivity that enables healthcare providers to remotely monitor patient adherence in real time, adjust dosing as needed, and receive alerts about potential issues—all while maintaining HIPAA compliance.
Addressing the Opioid Crisis and Beyond
Berkshire Biomedical sees significant potential for its technology in addressing the ongoing opioid epidemic. According to company data, only approximately 20% of the estimated 5.7 million Americans with opioid use disorder currently receive medication-assisted treatment.
"We believe that our proprietary, cloud-based, healthcare-enabled COPA device has the potential to dramatically increase the number of people with Opioid Use Disorder receiving medication treatment," Timberlake explained.
The company's initial focus will be on methadone delivery for OUD treatment, followed by applications for pain management involving controlled medications. Future plans include expanding COPA™ usage to a broader range of therapeutic areas and clinical applications.
NIH Support and Development Status
The COPA™ system's development is being supported by a $2.0 million Fast-Track Small Business Innovation Research grant from the National Institute of Drug Abuse (NIDA) of the National Institutes of Health under award number R44DA057185.
It's important to note that the system is still under development and has not yet received FDA review or authorization for commercial sale.
Upcoming Live Demonstration Webinar
As the equity crowdfunding campaign enters its final phase, Berkshire Biomedical has announced an exclusive webinar scheduled for April 8, 2025, at 1:30 PM PDT. The virtual event, titled "How COPA™ Delivers the Right Medication to the Right Person, in the Right Amount, at the Right Time," will provide potential investors and interested parties with a live demonstration of the technology.
The webinar will showcase the dual-biometric authentication process in action and offer insights into how the system supports patients, providers, and caregivers. Attendees will also have the opportunity to engage directly with Berkshire's leadership team during a live Q&A session.
Investment Opportunity Details
The equity crowdfunding campaign is currently live on StartEngine, with the company noting that this represents a limited-time opportunity for investors to participate in what they believe will be the future of personalized medication management.
Potential investors should be aware that, as with any early-stage investment, this opportunity involves significant risk. The company has explicitly stated that the investment is "speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment."
Those interested in learning more about the investment opportunity can visit StartEngine's Berkshire Offering Page or register for the upcoming webinar demonstration.
